Diliana Stoilova is a seasoned leader in the biotech and pharmaceutical sectors, bringing over 20 years of extensive experience in drug development to her role as Founder and Principal at DMS Biotech Consulting. With a robust background that spans the entire drug development lifecycle—from pre-Investigational...
Diliana Stoilova is a seasoned leader in the biotech and pharmaceutical sectors, bringing over 20 years of extensive experience in drug development to her role as Founder and Principal at DMS Biotech Consulting. With a robust background that spans the entire drug development lifecycle—from pre-Investigational New Drug (IND) applications to Biologics License Applications (BLA) and New Drug Applications (NDA)—Diliana has consistently demonstrated her ability to guide cross-functional teams through complex regulatory landscapes. Her expertise in FDA review processes and successful product launches positions her as a trusted advisor for biotech companies navigating the intricacies of drug development.
At DMS Biotech Consulting, Diliana leverages her comprehensive knowledge in program and portfolio management to provide strategic insights that drive innovation and efficiency in drug discovery and development. She is adept at aligning project planning with organizational goals, ensuring that each phase of development is meticulously executed and monitored. Her strong interpersonal communication skills facilitate effective collaboration among stakeholders, fostering an environment where ideas can flourish and challenges are met with actionable solutions.
Key projects under her leadership include optimizing drug development pathways for emerging biotech firms and streamlining processes to enhance product development timelines. Her in-depth understanding of biochemistry and cell biology, combined with her experience in the lifesciences sector, enables her to tackle complex scientific challenges head-on. As a thought leader in the industry, Diliana is committed to empowering biotech companies to achieve their objectives while navigating the ever-evolving landscape of drug development.
